Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said it has begun dosing patients with SLN360, a putative treatment for elevated Lipoprotein (a), ‘bad’ cholesterol associated with increased risk of heart disease.
The APOLLO phase I clinical study is designed to assess safety, tolerability and way the drug interacts with the body.
It will be a placebo-controlled trial, which means one group will receive the drug while the other will get a substance with no medical benefit. Around 88 people will be recruited to take part in the clinical assessment.
Silence is a specialist in delivering short interfering ribonucleic acid (siRNA), which are used to silence genes associated with disease.